WindRose Health Investors Commits $85 Million in Financing to Kidney Health Management Company Healthmap Solutions

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

TAMPA, FL / ACCESSWIRE / May 27, 2019 / Kidney health management industry leader Healthmap Solutions Inc. (“Healthmap” or the “Company”) announced today that WindRose Health Investors, LLC (“WindRose”), a New York-based healthcare private equity firm, has recapitalized the Company with a commitment of $85 million. Healthmap plans to use the funds to continue national expansion of its kidney health management services, and to support its unique model of assuming risk for reducing the cost of care for those with complex kidney health conditions.

“Financial backing from an investor of WindRose’s stature and expertise provides the extra strategic insights and capital required for us to accelerate our growth and to assume the financial risk of reducing the cost of care for those suffering from complex kidney health conditions,” said Joe Vattamattam, CEO of Healthmap. “We expect to provide these services in 12 states in 2020 and to continue to expand from there with a geographic expansion strategy that enables us to have an even deeper positive impact on the kidney population.”

Kidney disease impacts 30 million Americans, yet 90% of those with chronic kidney disease are unaware they have the condition, resulting in lower quality of care and higher costs. For those that progress to end stage renal disease, a significant opportunity exists to improve quality of life through home dialysis. Healthmap’s Kidney Health Management Program has been proven to detect the disease state early, align primary and specialty care with evidence-based guidelines and increase the use of home dialysis when appropriate, all while addressing behavioral health and social determinant of health barriers.

“We are thrilled to be partnering with Healthmap,” said Oliver Moses, Managing Partner with WindRose. “We have evaluated many businesses in this sector and have identified Healthmap as the premier platform. The Healthmap team has created a differentiated solution in an area of increasing focus for health plans, at-risk providers and self-insured employers. We look forward to supporting the Company’s continued growth.”

VERSARi Private Capital Advisory assisted Healthmap in arranging this financing. Johnson Pope Bokor Ruppel & Burns, LLP acted as legal advisor to Healthmap Solutions. Terms of the transaction were not disclosed.

About Healthmap

Healthmap is a kidney health management company serving health plans, including Medicare Advantage and employer-sponsored plans, as well as accountable care organizations (ACOs) and provider groups seeking value-based solutions that improve the clinical and financial performance for high-risk, high-cost kidney patient populations. The company has a rich history forged in data and analytics, having begun as a healthcare data clearing house, adding robust healthcare analytics expertise, and today Healthmap uses that experience to power complex kidney health management programs with its clinical experts. The company also provides similar integrated programs across the full range of specialty health population management. For more information email info@healthmapsolutions.com.

About WindRose Health Investors

WindRose Health Investors, LLC (“WindRose”) makes equity investments in companies that operate within the services sectors of the healthcare industry. They focus on companies with profitable business models and a demonstrated ability to deliver cost-effective solutions. WindRose manages over $1.4 billion in investments and is currently investing out of its fifth fund. They are based in New York City and invest in companies throughout the United States. For more information go to: windrose.com.

Contacts

Rebecca Rice
Rebecca@WilmarkGroup.com

SOURCE: Healthmap

View source version on accesswire.com:
https://www.accesswire.com/546499/WindRose-Health-Investors-Commits-85-Million-in-Financing-to-Kidney-Health-Management-Company-Healthmap-Solutions

user

Recent Posts

Best Skin Tag Remover 2025: Revitag Review & Top Skin Tag Removal Tips

Looking for the best skin tag remover in 2025? Discover how Revitag works, plus expert…

12 hours ago

Best Probiotic for Bloating, Gas, and Constipation: Top Probiotic Supplements for Gut Health to Reduce Bloating, Indigestion & Flatulence (YourBiology)

The best probiotics for bloating and gas include strains like Lactobacillus rhamnosus GG, Lactobacillus acidophilus,…

12 hours ago

Best Vyvanse Alternative Over the Counter for ADHD – Natural Vyvanse Substitute – Noocube

NooCube NooCube London, May 10, 2025 (GLOBE NEWSWIRE) -- Vyvanse is a prescription medication that…

12 hours ago

MEDVi Under Review: Best GLP-1 Semaglutide & Terzepatide Compound Solution for Personalized Weight Loss

A Comprehensive Review of MEDVi’s Personalized GLP-1 Weight Loss Solutions Featuring Affordable Compounded Semaglutide and…

12 hours ago

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology…

12 hours ago

Sumatra Slim Belly Tonic Reviews: 2025 Real User Reviews Analyzed & Verified (Blue Tonic for Weight Loss)

LOS ANGELES, May 10, 2025 (GLOBE NEWSWIRE) -- Losing weight these days can feel more…

1 day ago